Lindsay Klein
Family Medicine · Richmond, VANPI 1962963215
Payments from drug & device makers
Across 180 payments — averaging $19.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$572
- AstraZeneca$541
- Pfizer$376
- Lilly USA, LLC$282
- AbbVie$212
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$141
- plus $1K from 32 others
What the payments were for
- Food & beverage$3,535100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 32 | $572 |
| AstraZeneca(2 entities) | 13 | $541 |
| Pfizer | 23 | $376 |
| Lilly USA, LLC | 16 | $282 |
| AbbVie | 17 | $212 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $141 |
| Amgen | 7 | $137 |
| Bayer | 2 | $136 |
| Phathom Pharmaceuticals, Inc. | 2 | $130 |
| Boehringer Ingelheim | 8 | $130 |
| Teva Pharmaceuticals USA, Inc. | 6 | $97 |
| GSK | 5 | $85 |
| Xeris Pharmaceuticals, Inc. | 4 | $82 |
| Ardelyx, Inc. | 4 | $57 |
| Merck | 3 | $51 |
| Axsome Therapeutics, Inc. | 3 | $47 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $45 |
| Viatris Specialty LLC | 2 | $36 |
| Exact Sciences | 2 | $33 |
| Astellas Pharma US Inc | 2 | $31 |
| Dynavax Technologies Corporation | 1 | $24 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $23 |
| Biogen | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Vertex | 1 | $21 |
| Antares Pharma, Inc. | 1 | $20 |
| Philips North America LLC | 1 | $19 |
| Novartis | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Abiomed | 1 | $16 |
| Edwards Lifesciences | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Baxter Healthcare | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| TMS Neurohealth Centers Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,535 in reported general payments places this provider in the 85th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 52 | $68,255 |
| JardianceEmpagliflozin | 55 | $54,648 |
| EliquisApixaban | 23 | $28,072 |
| RybelsusSemaglutide | 16 | $21,131 |
| MounjaroTirzepatide | 19 | $19,686 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $5,211 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $2,932 |
| Rosuvastatin Calcium | 219 | $2,716 |
| Atorvastatin Calcium | 244 | $2,546 |
| SynthroidLevothyroxine Sodium | 39 | $1,386 |
| Pravastatin Sodium | 122 | $1,288 |
| Levothyroxine Sodium | 125 | $1,282 |
| Ezetimibe | 46 | $1,269 |
| Amlodipine Besylate | 292 | $1,240 |
| Metoprolol Succinate | 91 | $1,072 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $572 | $89,38668 claims |
| Boehringer IngelheimJardiance | $130 | $54,64855 claims |
| PfizerEliquis | $376 | $28,07223 claims |
| Lilly USA, LLCMounjaro | $282 | $19,68619 claims |
| AstraZenecaSymbicort | $541 | $5,21113 claims |
| AbbVieSynthroid | $212 | $1,38639 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $1,282125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Richmond
- Paul StairsRichmond$105K
- Edwin RobinsonRichmond$83K
- Banks TurnerRichmond$74K
- James FosterRichmond$27K
- George MaughanRichmond$21K
- Aaron HartmanMidlothian$17.4M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.